Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. **Registrant Name**
   - Organization/Lobbying Firm
   - Self Employed Individual
   - AstraZeneca Pharmaceuticals LP

2. **Address**
   - Address1: 1800 CONCORD PIKE, P.O. BOX 15437
   - City: WILMINGTON
   - State: DE
   - Zip Code: 19850-5437
   - Country: USA

3. **Principal place of business (if different than line 2)**
   - City
   - State
   - Zip Code
   - Country

4a. **Contact Name**
   - Ms. Jamie Bell

4b. **Telephone Number**
   - 2023505550

4c. **E-mail**
   - jamie.bell@astrazeneca.com

5. **Senate ID#**
   - 54073-12

6. **House ID#**
   - 349750000

7. **Client Name**
   - Self
   - Check if client is a state or local government or instrumentality
   - AstraZeneca Pharmaceuticals LP

8. **Year**
   - 2018

9. **Check if this filing amends a previously filed version of this report**
   - Yes

10. **Check if this is a Termination Report**
    - Yes

11. **No Lobbying Issue Activity**

12. **Lobbying**
    - INCOME relating to lobbying activities for this reporting period was:
      - Less than $5,000
      - $5,000 or more: $620,000.00
    - Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. **Organizations**
    - EXPENSE relating to lobbying activities for this reporting period were:
      - Less than $5,000
      - $5,000 or more: $620,000.00
    - 14. **REPORTING** Check box to indicate expense accounting method. See instructions for description of options.
      - Method A. Reporting amounts using LDA definitions only
      - Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
      - Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

14. **Signature**
    - Digitally Signed By: Jamie Bell
    - Date: 5/2/2019 12:22:41 PM
15. General issue area code HCR

16. Specific lobbying issues

American Health Care Act (HR 1628 House)
SYNC Act - Medication Adherence (House)
Value of Prescription Drugs
Chronic Care - Drug Adherence and Continuity of Care (S 870)
Price Transparency
Oncology
Personalized Medicine
Affordable and Safe Prescription Drug Importation Act - S 469
Vaccines for Children program

17. House(s) of Congress and Federal agencies □ Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC)

18. Name of each individual who acted as a lobbyist in this issue area

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>Covered Official Position (if applicable)</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theresa</td>
<td>Jolivette</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Christine</td>
<td>Bloomquist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natalie</td>
<td>Morris</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laura</td>
<td>Okpala</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helen</td>
<td>Dwight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morgan</td>
<td>Bradley-Jones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susie</td>
<td>Ahn</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. Interest of each foreign entity in the specific issues listed on line 16 above □ Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

<table>
<thead>
<tr>
<th>Medicare Part D Coverage and Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare Part D Non-Interference</td>
</tr>
<tr>
<td>Legislative proposals to change Medicare Part D</td>
</tr>
<tr>
<td>Medicare Part B coverage and reimbursement</td>
</tr>
<tr>
<td>Medicaid Coverage</td>
</tr>
<tr>
<td>Coverage Gap Discount</td>
</tr>
<tr>
<td>Cancer Care Payment Reform Act (S 463, H 1834)</td>
</tr>
<tr>
<td>Oncology Care Model - CMS</td>
</tr>
</tbody>
</table>

17. House(s) of Congress and Federal agencies

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>Covered Official Position (if applicable)</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christine</td>
<td>Bloomquist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natalie</td>
<td>Morris</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laura</td>
<td>Okpala</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helen</td>
<td>Dwight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morgan</td>
<td>Bradley-Jones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susie</td>
<td>Ahn</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

- Adherence & Medication Synchronization Bill/ SYNC Act – Medication Adherence (House)
- Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870)
- Medicare Telehealth Parity Act (H.R. 2550)
- Electronic prior authorization (ePA) bill (HR 4841) / H.R. 5773, the Preventing Addiction
- Cardiac Bundled Payment Model (HHS/CMMI)
- Medicare Part D coverage and reimbursement
- Value of Prescription Drugs, Senate & House
- Prescription Drug Importation, Senate & House
- Innovative Payment Models, Senate & House
- Price Transparency, Senate & House
- S. 251, Senate and House
- CDC Asthma Funding, Senate
- Legislative proposals to change Medicare Part D
- Medicaid and 340B issues & drug discount program
- President’s Drug Pricing Blueprint

17. House(s) of Congress and Federal agencies [ ] Check if None

- U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>Covered Official Position (if applicable)</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theresa</td>
<td>Jolivette</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natalie</td>
<td>Morris</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helen</td>
<td>Dwight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morgan</td>
<td>Bradley-Jones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susie</td>
<td>Ahn</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Christie</td>
<td>Bloomquist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laura</td>
<td>Okpala</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. Interest of each foreign entity in the specific issues listed on line 16 above [ ] Check if None

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>Zip Code</th>
<th>Country</th>
</tr>
</thead>
</table>

21. Client new principal place of business (if different than line 20)

<table>
<thead>
<tr>
<th>City</th>
<th>State</th>
<th>Zip Code</th>
<th>Country</th>
</tr>
</thead>
</table>

22. New General description of client’s business or activities

---

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
24. General lobbying issue that no longer pertains

25. Add the following affiliated organization(s)

Internet Address:

<table>
<thead>
<tr>
<th>Name</th>
<th>Street Address</th>
<th>Address</th>
<th>Principal Place of Business (city and state or country)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1  2  3

27. Add the following foreign entities:

<table>
<thead>
<tr>
<th>Name</th>
<th>Street Address</th>
<th>Address</th>
<th>Principal place of business (city and state or country)</th>
<th>Amount of contribution for lobbying activities</th>
<th>Ownership percentage in client</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1  3  5

2  4  6

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

☐ No  ☐ Yes

<table>
<thead>
<tr>
<th>Lobbyist Name</th>
<th>Description of Offense(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>